Compared to probucol alone, Tongxinluo combined with probucol significantly reduces serum levels of ox-LDL, MMP-7, and IL-18 in stroke patients, suggesting a potential role in delaying or reversing the progression of carotid atherosclerotic plaques. No significant adverse reactions were observed during the treatment period. This evidence concerns the gene IL18 and stroke disorder.